Purpose: This systematic analysis was conducted to evaluate the efficacy and safety of nedaplatin based salvagechemotherapy for treatment of patients with advanced cervical cancer.
Methods: Clinical studies evaluating theefficacy and safety of nedaplatin based regimens on response and safety for patients with cervical cancer wereidentified using a predefined search strategy. Pooled response rates (RRs) were calculated.
Results: For nedaplatinbased regimens, 5 clinical studies including 264 patients with advanced cervical cancer were considered eligiblefor inclusion. The analysis showed that, in all patients, pooled RR was 74.6% (197/264). Major adverse effectswere leukopenia, thrombocytopenia and nausea/vomiting. No treatment related death occurred with nedaplatinbased treatment.
Conclusion: This systematic analysis suggests that nedaplatin based regimens are associatedwith good activity with acceptable tolerability in treating patients with advanced cervical cancer.